The Psoriasis Treatment Market size was valued at USD 22.38 billion in 2023 and is projected to reach USD 54.40 billion by 2032, growing at a CAGR of 10.4% during the forecast period 2024-2032.
Get More Information on Psoriasis Treatment Market - Request Sample Report
This report shows the increasing prevalence and incidence of psoriasis, as well as distribution of severity and rate of diagnosis, impacting treatment demand. Regional patterns of treatment adoption trends are the subject of this research, highlighting disparities in access to topical treatments, biologics, and systemic therapies. The research also looks at the effect of biologic patent expiration and the increasing presence of biosimilars, which are redefining market rivalry and price dynamics. The report also addresses patient preference and satisfaction trends, indicating a move toward more personalized treatment strategies and better long-term disease control. In addition, it assesses the growing role of digital health and telemedicine in psoriasis management, improving patient activation, remote consultations, and therapy compliance.
Drivers
The increasing prevalence of psoriasis worldwide, affecting approximately 125 million people globally.
The increasing adoption of biologic treatments, such as TNF and IL inhibitors, has resulted in improved management of the disease, resulting in increased treatment needs. New advances in drug discovery, such as targeted immunotherapies and JAK inhibitors, have improved treatment options and patient outcomes. Increased awareness drives by organizations like the National Psoriasis Foundation (NPF) and the International Federation of Psoriasis Associations (IFPA) have enhanced early diagnosis and increased patient access to sophisticated treatments. In addition, pharma firms are heavily investing in R&D and clinical trials, and medicines such as Bimekizumab (UCB) and Mirikizumab (Eli Lilly) are yielding positive results. The trend towards personalized medicine and precision therapies is also a major driving force, enhancing efficacy while minimizing side effects. In addition, increasing healthcare coverage and insurance reimbursement policies in developed and emerging markets are making treatment more accessible. The increasing use of teledermatology and electronic health solutions is also making it easier for early consultation and renewal of prescriptions, leading to improved disease control. With an aging population and increased comorbidities like psoriatic arthritis, cardiovascular conditions, and metabolic syndrome, the need for effective therapy for psoriasis is likely to increase.
Restraints
The high treatment costs and limited affordability remain significant restraints in the psoriasis treatment market.
Biologic treatments, including Stelara (J&J) and Cosentyx (Novartis), run up to USD 30,000–USD 80,000 per year for patients, which makes them unaffordable for most, especially in low- and middle-income nations. Poor insurance coverage and high out-of-pocket costs further limit patient access, leading many to use older, less potent drugs such as topical corticosteroids and methotrexate. Yet another principal impediment is the extended process of regulatory approvals since stringent requirements of efficacy and safety for a therapy keep delaying their market debut. The drugs, particularly the biologics, have stricter measures of pharmacovigilance imposed because they are immunosuppressant, lengthening the timeframe before their broader availability on the market. Safety concerns and side effects, as with more threats to infections and cancer risk due to biologics, further reduce patient long-term compliance. Competition from generic and biosimilar forms is also another threat to major pharma firms, as biosimilars such as Cyltezo (Boehringer Ingelheim) dampen the pricing edge of first-in-class biologics. Further, inadequate awareness and misdiagnosis in some areas stop early treatment, and hence disease progression occurs. Hospital-based administration of most injectable biologics also limits patient convenience and thereby lowers the adoption rates of those looking for self-administrative treatments.
Opportunities
The growing demand for novel biologic and small-molecule therapies presents significant opportunities in the psoriasis treatment market.
The surge in investment in new-generation IL and JAK inhibitors has given rise to promising products, including Bimekizumab (IL-17A/IL-17F inhibitor) and Deucravacitinib (TYK2 inhibitor), with enhanced efficacy and safety profiles. The growth in biosimilar products, including Hulio (Biocon) and Hadlima (Samsung Bioepis), is likely to push affordability and accessibility, particularly in price-sensitive markets. Also, the coupling of AI and telemedicine in dermatology is simplifying psoriasis diagnosis and treatment planning, taking the workload off the healthcare providers. Increasing demand for oral and topical agents over injectables is offering scope for drug companies to formulate more patient-acceptable therapies with higher compliance. Increasing awareness through patient support groups, social media campaigns, and educational programs for dermatologists is also increasing early diagnosis rates. With increasing incidences of psoriatic arthritis (occurring in 30% of patients with psoriasis), firms are concentrating on two-in-one drugs that treat both diseases, providing a larger market potential. Additionally, drug collaborations for combination treatments—like biologics and PDE4 inhibitors or vitamin D analogs—are providing new opportunities for effective, multi-targeted treatment modalities.
Challenges
One of the biggest challenges in the psoriasis treatment market is the long-term management and relapse rates associated with the disease.
Psoriasis is an autoimmune, chronic, and recurring disease, which must be treated for life, but patients often get tired of treatment and stop it because of side effects, expense, or loss of efficacy. The other issue is the absence of treatment guidelines for everyone since response to biologics is different in various patients and causes trial-and-error prescribing practices. Drug resistance and treatment failure are also issues since some patients form neutralizing antibodies against biologics, which decrease the efficacy of these drugs with time. Furthermore, although there have been drastic improvements, patient compliance rates are still low, especially for systemic treatments, as fears regarding immunosuppression and long-term side effects deter consistent use. Few clinical studies concerning pediatric psoriasis also pose issues in treatment of the condition in younger groups, limiting the access to licensed medicines. The exorbitant R&D expenses and long FDA/EMA approval processes slow down the launch of innovative drugs, restricting market growth. Another increasing issue is healthcare disparity, where access to biologic treatments is strongly biased towards developed countries, with most areas depending on outdated therapies. To overcome these challenges will need greater patient education, better drug affordability, and creative treatment approaches to facilitate continued market growth.
By Drugs Class
Tumor Necrosis Factor (TNF) inhibitors dominated the market with 41.4% share in 2023. Their dominance is due to their proven efficacy in controlling moderate-to-severe psoriasis, universal physician preference, and robust clinical evidence for long-term disease control. Top-selling drugs like adalimumab and etanercept remain popular because of their well-established safety profiles and extensive insurance coverage.
Interleukin (IL) inhibitors are anticipated to see the most rapid growth during the forecast period. This is because they have greater efficacy, more targeted mechanism of action, and better safety profiles than TNF inhibitors. IL-17 and IL-23 inhibitors such as secukinumab, ixekizumab, and risankizumab have been seen to be very effective in showing higher skin clearance rates, and hence, have seen greater uptake among dermatologists and patients who desire improved long-term disease control.
By Route of Administration
The parenteral segment dominated the psoriasis treatment market in 2023, mainly owing to the demand for biologic treatments, which are delivered through infusion or injection. Biologic medicines, specifically TNF inhibitors and IL inhibitors, have been established as the preferred treatment option for moderate-to-severe psoriasis patients and thus drove the dominance of this segment. The capability of such medications to yield prolonged remission along with a high level of patient compliance further established their dominance in the market.
The topical segment is anticipated to grow at the highest rate, driven by the growing need for first-line treatment among patients with mild-to-moderate psoriasis. Topical corticosteroids and vitamin D analogs continue to be most sought after due to the ease of application and the lack of systemic side effects. Furthermore, continuous developments in new topical formulations, including foam-based and combination therapies, are improving treatment outcomes and patient adherence, propelling market growth in the future.
By Distribution Channel
Hospital pharmacies held the highest market share of 40.8% in 2023. The segment's dominance is largely attributed to the high volume of biologic therapy prescriptions, which tend to be initiated and maintained in hospital environments under specialist care. Hospital pharmacies also have a significant role in offering advanced treatment for severe psoriasis cases, making high-cost drugs accessible that need professional administration.
Retail pharmacies are expected to increase at the highest rate, spurred by increasing availability of psoriasis treatments in community pharmacy outlets. The increased use of self-administered biologics, oral therapy, and topical therapy has increased prescription volumes filled in retail pharmacies. Moreover, increasing specialty pharmacy services and direct-to-patient models of distribution have improved accessibility, and retail pharmacies have emerged as a growth driver in the market.
North America held the largest market share of psoriasis treatment worldwide in 2023, taking up 36.4% of the global market share. This is because the region boasts a high rate of psoriasis prevalence, augmented by robust healthcare infrastructure, friendly reimbursement policies, and extensive adoption of sophisticated biologic therapies. The availability of major pharmaceutical firms such as AbbVie, Amgen, and Johnson & Johnson has further boosted market growth through persistent product development and strategic partnerships. The increasing awareness of psoriasis as an autoimmune disease has also resulted in early detection and greater patient exposure to targeted drugs. The U.S. is still the most contributing country in North America, backed by a high prescription rate of biologics like TNF and IL inhibitors and active research and development with the aim for new treatment paradigms.
The Asia-Pacific market is anticipated to record the most rapid growth during the forecast period. The drivers of market growth here include rising prevalence of psoriasis, enhanced healthcare infrastructure, and growing patient affordability. China, India, and Japan are seeing a high rate of biologic drug uptake, facilitated by regulatory approval and increased awareness of sophisticated treatments. The rise in healthcare coverage and heightened interest in dermatology conditions are also driving the growth of the market in the region at a high rate.
Get Customized Report as per Your Business Requirement - Request For Customized Report
AbbVie Inc. – Humira, Skyrizi
Amgen Inc. – Enbrel, Otezla
Johnson & Johnson Services, Inc. – Stelara, Tremfya
Novartis AG – Cosentyx
Eli Lilly and Company – Taltz, Olumiant
AstraZeneca – Saphnelo (under research for psoriasis applications)
Celgene Corporation (acquired by Bristol-Myers Squibb) – Otezla
UCB S.A. – Bimzelx
Merck
Boehringer Ingelheim International GmbH – Spesolimab (under development for psoriasis)
Recent Developments
In March 2025, Takeda focused on addressing clinical disparities in psoriasis research, highlighting the condition’s impact on over 7.5 million Americans and 60 million people globally. The company emphasized the significant comorbidities associated with psoriasis, including cardiovascular disease, psoriatic arthritis, and depression, as well as its effects on quality of life, stigmatization, and work productivity.
In Jan 2025, Biocon's shares surged by 8% following Japan's approval of its psoriasis drug, ustekinumab, for treating psoriasis vulgaris and psoriatic arthritis (PsA). The approval led to an upgrade by Jefferies, highlighting a significant market development in Biocon’s dermatology portfolio.
|
Report Attributes |
Details |
|
Market Size in 2023 |
USD 22.38 billion |
|
Market Size by 2032 |
USD 54.40 billion |
|
CAGR |
CAGR of 10.4% From 2024 to 2032 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2032 |
|
Historical Data |
2020-2022 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
• By Drugs Class [Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteriods, Others] |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
|
Company Profiles |
AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Novartis AG, Eli Lilly and Company, AstraZeneca, Celgene Corporation (a Bristol-Myers Squibb company), UCB S.A., Merck, Boehringer Ingelheim International GmbH. |
Ans: The Psoriasis Treatment Market Size was valued at USD 22.38 billion in 2023 and is expected to reach USD 54.40 billion by 2032 and grow at a CAGR of 10.4% over the forecast period 2024-2032.
ANS: AbbVie Inc, Novartis AG, Merck & CO, Inc, Amgen, UCB, Sun pharmaceutical Industries Ltd., Pfizer, Johnson & Johnson, Eli Lilly and Company, Leo pharma A/S and others.
ANS: The rise in the demand for the psoriasis treatment.
Ans: Market is divided into three segments.
Ans: The high treatment costs and limited affordability remain significant restraints in the psoriasis treatment market.
Table of contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Psoriasis (2023)
5.2 Severity Distribution and Diagnosis Rates (2023)
5.3 Treatment Adoption Trends (2023), by Region
5.4 Biologic Patent Expiry and Biosimilar Market Entry (2023-2032)
5.5 Patient Preferences and Satisfaction Trends (2023)
5.6 Digital Health and Telemedicine Adoption for Psoriasis Care
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Psoriasis Treatment Market Segmentation, by Drugs Class
7.1 Chapter Overview
7.2 Tumor Necrosis Factor Inhibitors
7.2.1 Tumor Necrosis Factor Inhibitors Market Trends Analysis (2020-2032)
7.2.2 Tumor Necrosis Factor Inhibitors Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Interleukin Inhibitors
7.3.1 Interleukin Inhibitors Market Trends Analysis (2020-2032)
7.3.2 Interleukin Inhibitors Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Vitamin D Analogues
7.4.1 Vitamin D Analogues Market Trends Analysis (2020-2032)
7.4.2 Vitamin D Analogues Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Corticosteriods
7.5.1 Corticosteriods Market Trends Analysis (2020-2032)
7.5.2 Corticosteriods Market Size Estimates and Forecasts to 2032 (USD Million)
7.6 Others
7.6.1 Others Market Trends Analysis (2020-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
8. Psoriasis Treatment Market Segmentation, by Route of Administration
8.1 Chapter Overview
8.2 Oral
8.2.1 Oral Market Trends Analysis (2020-2032)
8.2.2 Oral Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Parenteral
8.3.1 Parenteral Market Trends Analysis (2020-2032)
8.3.2 Parenteral Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Topical
8.4.1 Topical Market Trends Analysis (2020-2032)
8.4.2 Topical Market Size Estimates and Forecasts to 2032 (USD Million)
9. Psoriasis Treatment Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Psoriasis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.4 North America Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.5 North America Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.6.2 USA Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.6.3 USA Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.7.2 Canada Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.7.3 Canada Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.8.2 Mexico Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.8.3 Mexico Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Psoriasis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.6.2 Poland Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.6.3 Poland Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.7.2 Romania Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.7.3 Romania Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.8.2 Hungary Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.8.3 Hungary Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.9.2 Turkey Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.9.3 Turkey Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Psoriasis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.4 Western Europe Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.5 Western Europe Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.6.2 Germany Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.6.3 Germany Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.7.2 France Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.7.3 France Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.8.2 UK Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.8.3 UK Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.9.2 Italy Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.9.3 Italy Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.10.2 Spain Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.10.3 Spain Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.13.2 Austria Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.13.3 Austria Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Psoriasis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.4 Asia Pacific Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.5 Asia Pacific Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.6.2 China Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.6.3 China Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.7.2 India Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.7.3 India Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.8.2 Japan Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.8.3 Japan Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.9.2 South Korea Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.9.3 South Korea Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.10.2 Vietnam Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.10.3 Vietnam Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.11.2 Singapore Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.11.3 Singapore Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.12.2 Australia Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.12.3 Australia Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Psoriasis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.4 Middle East Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.5 Middle East Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.6.2 UAE Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.6.3 UAE Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.7.2 Egypt Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.7.3 Egypt Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.9.2 Qatar Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.9.3 Qatar Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Psoriasis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.4 Africa Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.5 Africa Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.6.2 South Africa Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.6.3 South Africa Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Psoriasis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.4 Latin America Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.5 Latin America Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.6.2 Brazil Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.6.3 Brazil Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.7.2 Argentina Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.7.3 Argentina Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.8.2 Colombia Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.8.3 Colombia Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Psoriasis Treatment Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Psoriasis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Psoriasis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11. Company Profiles
11.1 AbbVie Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 Amgen Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Johnson & Johnson Services, Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 Eli Lilly and Company
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 AstraZeneca
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Celgene Corporation (a Bristol-Myers Squibb company)
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 UCB S.A.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 Merck
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Boehringer Ingelheim International GmbH
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Drugs Class
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin D Analogues
Corticosteriods
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Sharps Containers Market Size was valued at USD 584.5 Million in 2023 and is expected to reach USD 869.4 Million by 2032 and grow at a CAGR of 4.57% over the forecast period 2024-2032.
The Cholesterol Test Market was valued at USD 8.3 Bn in 2023 and is expected to reach USD 16.8 billion in 2032, growing at a CAGR of 8.17% from 2024 to 2032.
The Leukapheresis Market valued at USD 192 Million in 2023, projected to reach USD 491.05 Million by 2032, growing at an 11.01% CAGR from 2024 to 2032.
The Neuroprosthetics Market size was valued at USD 12.69 billion in 2023 and is expected to reach USD 38.93 billion by 2032, growing at a CAGR of 13.28%.
The Neuroscience Market Size was valued at USD 35.3 billion in 2023 and is expected to reach USD 50.2 Billion by 2032, at 4.00% CAGR by 2024-2032
The Healthcare Interoperability Solutions Market Size was valued at USD 3.4 billion in 2023 and is expected to reach USD 10.9 billion by 2032 and grow at a CAGR of 13.8% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
